377 related articles for article (PubMed ID: 16109114)
21. The effect of social factors on the anxiolytic efficacy of buspirone in male rats, male mice, and men.
Majercsik E; Haller J; Leveleki C; Baranyi J; Halász J; Rodgers RJ
Prog Neuropsychopharmacol Biol Psychiatry; 2003 Dec; 27(8):1187-99. PubMed ID: 14659474
[TBL] [Abstract][Full Text] [Related]
22. Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
Mathew NT; Finlayson G; Smith TR; Cady RK; Adelman J; Mao L; Wright P; Greenberg SJ;
Headache; 2007 Feb; 47(2):189-98. PubMed ID: 17300358
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and tolerability of sumatriptan injection for the treatment of morning migraine: two multicenter, prospective, randomized, double-blind, controlled studies in adults.
Winner P; Adelman J; Aurora S; Lener ME; Ames M
Clin Ther; 2006 Oct; 28(10):1582-91. PubMed ID: 17157114
[TBL] [Abstract][Full Text] [Related]
24. Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS).
Freitag FG; Finlayson G; Rapoport AM; Elkind AH; Diamond ML; Unger JR; Fisher AC; Armstrong RB; Hulihan JF; Greenberg SJ;
Headache; 2007 Apr; 47(4):519-30. PubMed ID: 17445101
[TBL] [Abstract][Full Text] [Related]
25. Estazolam treatment of insomnia in generalized anxiety disorder: a placebo-controlled study.
Post GL; Patrick RO; Crowder JE; Houston J; Ferguson JM; Bielski RJ; Bailey L; Pearlman HG; Shu VS; Pierce MW
J Clin Psychopharmacol; 1991 Aug; 11(4):249-53. PubMed ID: 1918423
[TBL] [Abstract][Full Text] [Related]
26. Buspirone: multicenter efficacy study.
Wheatley D
J Clin Psychiatry; 1982 Dec; 43(12 Pt 2):92-4. PubMed ID: 6130079
[TBL] [Abstract][Full Text] [Related]
27. Depression and anxiety: effect on the migraine-obesity relationship.
Tietjen GE; Peterlin BL; Brandes JL; Hafeez F; Hutchinson S; Martin VT; Dafer RM; Aurora SK; Stein MR; Herial NA; Utley C; White L; Khuder SA
Headache; 2007 Jun; 47(6):866-75. PubMed ID: 17578537
[TBL] [Abstract][Full Text] [Related]
28. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial.
Winner P; Linder SL; Lipton RB; Almas M; Parsons B; Pitman V
Headache; 2007 Apr; 47(4):511-8. PubMed ID: 17445100
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of buspirone in smoking cessation: a placebo-controlled trial.
Schneider NG; Olmstead RE; Steinberg C; Sloan K; Daims RM; Brown HV
Clin Pharmacol Ther; 1996 Nov; 60(5):568-75. PubMed ID: 8941030
[TBL] [Abstract][Full Text] [Related]
30. Early response and 8-week treatment outcome in GAD.
Rynn M; Khalid-Khan S; Garcia-Espana JF; Etemad B; Rickels K
Depress Anxiety; 2006; 23(8):461-5. PubMed ID: 16845651
[TBL] [Abstract][Full Text] [Related]
31. Valdecoxib for treatment of a single, acute, moderate to severe migraine headache.
Kudrow D; Thomas HM; Ruoff G; Ishkanian G; Sands G; Le VH; Brown MT
Headache; 2005 Oct; 45(9):1151-62. PubMed ID: 16178945
[TBL] [Abstract][Full Text] [Related]
32. Effect of early intervention with almotriptan vs placebo on migraine-associated functional disability: results from the AEGIS Trial.
Freitag F; Smith T; Mathew N; Rupnow M; Greenberg S; Mao L; Finlayson G; Wright P; Biondi D;
Headache; 2008 Mar; 48(3):341-54. PubMed ID: 18302700
[TBL] [Abstract][Full Text] [Related]
33. Meta-analysis of the safety and tolerability of two dose regimens of buspirone in patients with persistent anxiety.
Sramek JJ; Hong WW; Hamid S; Nape B; Cutler NR
Depress Anxiety; 1999; 9(3):131-4. PubMed ID: 10356651
[TBL] [Abstract][Full Text] [Related]
34. Effectiveness of yoga therapy in the treatment of migraine without aura: a randomized controlled trial.
John PJ; Sharma N; Sharma CM; Kankane A
Headache; 2007 May; 47(5):654-61. PubMed ID: 17501846
[TBL] [Abstract][Full Text] [Related]
35. Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone.
Petracca A; Nisita C; McNair D; Melis G; Guerani G; Cassano GB
J Clin Psychiatry; 1990 Sep; 51 Suppl():31-9. PubMed ID: 2211564
[TBL] [Abstract][Full Text] [Related]
36. Buspirone and diazepam in anxiety: a controlled study.
Rickels K; Weisman K; Norstad N; Singer M; Stoltz D; Brown A; Danton J
J Clin Psychiatry; 1982 Dec; 43(12 Pt 2):81-6. PubMed ID: 6130078
[TBL] [Abstract][Full Text] [Related]
37. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
Piskulić D; Olver JS; Maruff P; Norman TR
Hum Psychopharmacol; 2009 Aug; 24(6):437-46. PubMed ID: 19637398
[TBL] [Abstract][Full Text] [Related]
38. Buspirone and lorazepam in the treatment of generalized anxiety disorder in outpatients.
Laakmann G; Schüle C; Lorkowski G; Baghai T; Kuhn K; Ehrentraut S
Psychopharmacology (Berl); 1998 Apr; 136(4):357-66. PubMed ID: 9600581
[TBL] [Abstract][Full Text] [Related]
39. Effects of citalopram treatment on hypothermic and hormonal responses to the 5-HT1A receptor agonist buspirone in patients with major depression and therapeutic response.
Navinés R; Martín-Santos R; Gómez-Gil E; Martínez de Osaba MJ; Imaz ML; Gastó C
Psychoneuroendocrinology; 2007 May; 32(4):411-6. PubMed ID: 17337123
[TBL] [Abstract][Full Text] [Related]
40. The effect of propranolol on glyceryltrinitrate-induced headache and arterial response.
Tvedskov JF; Thomsen LL; Thomsen LL; Iversen HK; Williams P; Gibson A; Jenkins K; Peck R; Olesen J
Cephalalgia; 2004 Dec; 24(12):1076-87. PubMed ID: 15566422
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
